Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2010 Financial Results on November 1, 201

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2010 financial results on Monday, November 1, 2010, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Monday, November 1, 2010

2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET)

  • Telephone (877) 941-8632 (domestic) or (480) 629-9820 (international); conference ID 4373835
  • Webcast available at http://www.seattlegenetics.com in the Investors and News section

REPLAY access

  • Telephone replay will be available beginning at approximately 4:00 p.m. PT on November 1, 2010 through 4:00 p.m. PT on November 3, 2010 by calling (800) 406-7325 (domestic) or (303) 590-3030 (international); conference ID 4373835
  • Webcast replay will be available on the Seattle Genetics website at http://www.seattlegenetics.com in the Investors and News section

About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company recently reported positive top-line data from both a pivotal Hodgkin lymphoma trial and phase II anaplastic large cell lymphoma trial with its lead product candidate, brentuximab vedotin, and plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first half of 2011. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.



CONTACT:

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
[email protected]

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.